tiprankstipranks
Trending News
More News >
Benchmark Holdings (GB:BMK)
:BMK
Advertisement

Benchmark Holdings (BMK) AI Stock Analysis

Compare
3 Followers

Top Page

GB:BMK

Benchmark Holdings

(LSE:BMK)

Rating:50Neutral
Price Target:
23.00p
▲(8.49% Upside)
Benchmark Holdings' financial performance is mixed, with challenges in operational efficiency and revenue trends. Technical indicators suggest bearish momentum. However, positive corporate events, including strategic resolutions and significant asset sale profits, provide some optimism.

Benchmark Holdings (BMK) vs. iShares MSCI United Kingdom ETF (EWC)

Benchmark Holdings Business Overview & Revenue Model

Company DescriptionBenchmark Holdings (BMK) is a leading aquaculture, animal health, and advanced breeding company focused on delivering sustainable solutions for the global food industry. Operating in the sectors of aquaculture and agriculture, Benchmark provides a range of products and services including genetics, health products, and nutrition solutions to improve the productivity and sustainability of farmed fish and livestock. The company is dedicated to enhancing food security while promoting responsible farming practices.
How the Company Makes MoneyBenchmark Holdings generates revenue through several key streams, primarily from its aquaculture and animal health divisions. The aquaculture segment earns money by providing advanced breeding solutions and genetics for farmed fish, which includes a focus on disease resistance and growth efficiency. The animal health division offers a portfolio of health products, including vaccines and therapeutics, contributing significantly to the company's revenue. Additionally, Benchmark generates income from its nutrition solutions that enhance feed efficiency and animal performance. Strategic partnerships with farms and distributors in various regions also play a crucial role in its earnings, as these collaborations help expand its market reach and customer base.

Benchmark Holdings Financial Statement Overview

Summary
Benchmark Holdings presents a mixed financial picture. Despite a healthy equity position and improved cash flow management, ongoing operational losses and declining revenues are concerning. Strategic actions are needed to enhance financial stability.
Income Statement
45
Neutral
Benchmark Holdings has experienced fluctuating revenues, with a significant decline in the TTM period. The gross profit margin has deteriorated from prior years, and while there was a significant net income in the TTM period, it may be due to extraordinary items rather than operational efficiency. EBIT and EBITDA margins are negative, indicating ongoing operational challenges.
Balance Sheet
55
Neutral
The company maintains a healthy equity position with a debt-to-equity ratio that suggests manageable leverage. However, the equity ratio has decreased over the years, reflecting increased liabilities. The TTM shows an improvement in cash positions, which enhances liquidity, but declining total assets over time could be concerning.
Cash Flow
60
Neutral
Benchmark Holdings has improved its free cash flow in the TTM period, indicating better cash management. The operating cash flow to net income ratio suggests the company is generating cash efficiently relative to its reported income. However, consistent negative free cash flow in prior periods indicates past difficulties in generating cash.
BreakdownTTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue50.77M90.36M169.48M158.28M125.06M105.56M
Gross Profit24.26M43.95M86.75M83.13M65.58M54.96M
EBITDA-2.81M3.96M34.20M28.35M24.36M14.34M
Net Income46.00M-39.46M-23.15M-30.45M-11.58M-22.77M
Balance Sheet
Total Assets424.29M384.90M471.30M526.57M481.99M489.04M
Cash, Cash Equivalents and Short-Term Investments207.51M23.09M36.52M36.40M39.46M71.61M
Total Debt81.61M72.07M102.00M110.14M120.39M109.16M
Total Liabilities121.45M160.63M188.68M203.29M202.39M193.59M
Stockholders Equity302.83M218.26M276.40M313.40M271.71M289.13M
Cash Flow
Free Cash Flow2.54M-1.92M13.22M-1.91M-16.93M-15.47M
Operating Cash Flow6.81M2.00M20.00M10.81M5.79M-4.06M
Investing Cash Flow180.44M-2.83M-5.27M-11.22M-23.09M30.38M
Financing Cash Flow67.00K-10.97M-12.33M-6.92M-14.67M30.13M

Benchmark Holdings Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price21.20
Price Trends
50DMA
23.37
Negative
100DMA
22.76
Negative
200DMA
26.99
Negative
Market Momentum
MACD
-0.58
Negative
RSI
48.61
Neutral
STOCH
68.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BMK, the sentiment is Neutral. The current price of 21.2 is below the 20-day moving average (MA) of 21.94, below the 50-day MA of 23.37, and below the 200-day MA of 26.99, indicating a neutral trend. The MACD of -0.58 indicates Negative momentum. The RSI at 48.61 is Neutral, neither overbought nor oversold. The STOCH value of 68.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:BMK.

Benchmark Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
£182.13M33.805.04%1.89%-0.17%592.46%
63
Neutral
£76.19M100.001.00%
63
Neutral
$20.97B14.57-8.07%3.14%2.79%-9.97%
62
Neutral
£49.80M29.521.99%-10.99%60.65%
56
Neutral
£400.38M-369.20%4.50%74.32%
50
Neutral
£130.46M
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:BMK
Benchmark Holdings
22.05
-16.40
-42.65%
GB:VLG
Venture Life
59.00
13.00
28.26%
GB:EAH
Eco Animal Health
73.50
-27.50
-27.23%
GB:ANCR
Animalcare
265.00
-2.78
-1.04%
GB:AGY
Allergy Therapeutics
8.40
3.60
75.00%

Benchmark Holdings Corporate Events

Delistings and Listing Changes
Benchmark Holdings Concludes Trading on Euronext and AIM
Neutral
Aug 15, 2025

Benchmark Holdings plc announced that today marks the last day of trading for its shares on Euronext Growth Oslo and AIM, following the approval of its delisting application by Euronext Oslo Børs. This strategic move may impact the company’s market presence and trading dynamics, potentially affecting stakeholders who have invested in these exchanges.

Delistings and Listing ChangesBusiness Operations and Strategy
Benchmark Holdings to Delist Shares from Euronext Growth Oslo and AIM
Neutral
Aug 8, 2025

Benchmark Holdings has announced that Euronext Oslo Børs has approved its request to delist its shares from Euronext Growth Oslo, following a shareholder resolution and the satisfaction of certain conditions. The company’s shares will cease trading on both Euronext Growth Oslo and AIM, with the cancellations becoming effective on 18 August 2025. This strategic move may impact Benchmark’s market presence and stakeholder engagement.

Regulatory Filings and Compliance
Benchmark Holdings Updates Total Voting Rights After Tender Offer
Neutral
Jul 31, 2025

Benchmark Holdings PLC, a company involved in the aquaculture industry, has announced changes in its total voting rights following a tender offer and the exercise of employee options. As of July 31, 2025, the company’s issued share capital consists of 615,377,895 ordinary shares, all with voting rights. This change impacts the calculation for shareholders to notify their interest in the company. The Concert Party’s interests now account for 85.5% of the company’s total voting rights, with significant holdings by FERD AS, JNE Master Fund, and Kverva Finans AS.

Delistings and Listing ChangesStock BuybackBusiness Operations and Strategy
Benchmark Holdings Concludes Tender Offer, Cancels Shares
Neutral
Jul 25, 2025

Benchmark Holdings announced the results of its Tender Offer, where it successfully purchased and will cancel 127,720,171 Ordinary Shares, returning approximately £31.9 million to shareholders. This move is part of Benchmark’s strategic plan to conclude discussions with Oslo Børs regarding the cancellation of its shares from Euronext Oslo, impacting its market positioning and shareholder structure.

Delistings and Listing ChangesStock BuybackBusiness Operations and Strategy
Benchmark Holdings Completes Tender Offer, Cancels Shares
Neutral
Jul 25, 2025

Benchmark Holdings announced the results of its Tender Offer, where 127,720,171 Ordinary Shares were purchased and will be canceled, returning approximately £31.9 million to shareholders. This move is part of Benchmark’s strategic plan to conclude discussions with Oslo Børs regarding the cancellation of its shares from Euronext Oslo, impacting the company’s trading and shareholder structure.

Delistings and Listing ChangesExecutive/Board ChangesBusiness Operations and Strategy
Benchmark Holdings Announces Strategic Board and Management Changes
Neutral
Jul 21, 2025

Benchmark Holdings has announced significant changes to its board and management, effective from mid to late August 2025. Patrick Waty will take over as CEO, and Pierre Hugo will become CFO, among other board changes. These shifts are part of a strategic move following the company’s anticipated de-listing, potentially impacting its operational focus and stakeholder dynamics.

Delistings and Listing ChangesBusiness Operations and Strategy
Benchmark Holdings Announces Strategic Delisting and Tender Offer
Neutral
Jul 1, 2025

Benchmark Holdings has announced the approval of its proposals to return the majority of net proceeds from the sale of its Genetics Business to shareholders, delist from AIM and Euronext Growth Oslo, and re-register as a private limited company. The tender offer will open on July 3, 2025, and the delisting from Euronext Growth Oslo is expected to follow the completion of the tender offer. These strategic moves are aimed at streamlining operations and focusing on core business areas, potentially impacting shareholders and market positioning.

Regulatory Filings and Compliance
Benchmark Holdings Updates Total Voting Rights
Neutral
Jun 30, 2025

Benchmark Holdings PLC, a company involved in the aquaculture industry, announced that its total issued share capital now consists of 742,423,113 ordinary shares, all with voting rights. This increase in share capital is attributed to the routine exercise of options by current and former employees under the company’s block admission, impacting the calculation of shareholder interests.

Regulatory Filings and Compliance
Benchmark Holdings Updates Total Voting Rights
Neutral
Jun 30, 2025

Benchmark Holdings PLC, a company involved in the aquaculture industry, announced that as of June 30, 2025, its total issued share capital consists of 742,423,113 ordinary shares, all with voting rights. This increase in share capital is attributed to the routine exercise of options by current and former employees under the company’s block admission. The updated share capital figure will be used by shareholders to determine their interest or changes in their interest in the company.

Delistings and Listing ChangesShareholder MeetingsBusiness Operations and Strategy
Benchmark Holdings Secures Shareholder Approval for Strategic Resolutions
Positive
Jun 18, 2025

Benchmark Holdings announced that all resolutions at their General Meeting were approved, including a tender offer, de-listing, and re-registration. This approval signifies strong shareholder support and could impact the company’s strategic direction and market presence. Additionally, the company was informed of a recapitalization arrangement involving Mavenir Systems Inc., where the Chair of Benchmark, Nathan ‘Tripp’ Lane, is a board director.

Delistings and Listing ChangesM&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Benchmark Holdings Reports £76m Profit, Plans Delisting and Capital Return
Positive
Jun 12, 2025

Benchmark Holdings reported a £76 million profit for the first half of 2025, primarily driven by the £90.9 million gain from the sale of its Genetics business. The company plans to return capital to shareholders and delist from AIM and Euronext Growth Oslo. Despite a 22% decline in group revenues from continuing activities, the company has shown improvements in Advanced Nutrition and maintained solid performance in its Health segment. The restructuring following the Genetics sale is expected to streamline operations and reduce costs, positioning Benchmark for future growth. The company is also preparing for the relaunch of Ectosan® Vet and CleanTreat® with a new land-based model.

Financial Disclosures
Benchmark Holdings Adjusts Webcast Timing for Interim Results Announcement
Neutral
Jun 6, 2025

Benchmark Holdings plc has announced a change in the timing of its Equity Development webcast for retail investors, which will now occur at 10.00am UK time on Thursday, 12 June 2025. This webcast is part of the company’s release of its unaudited interim results for the six-month period ending 31 March 2025. The change in schedule reflects the company’s commitment to engaging with its investors and stakeholders, potentially impacting investor relations and market perception.

Financial Disclosures
Benchmark Holdings to Announce Interim Results on 12 June 2025
Neutral
May 27, 2025

Benchmark Holdings plc has announced that it will release its unaudited interim results for the six-month period ending 31 March 2025 on 12 June 2025. The announcement will be accompanied by presentations for analysts, institutional investors, retail investors, and wealth managers, indicating the company’s commitment to transparency and engagement with its stakeholders.

Delistings and Listing ChangesM&A TransactionsDividendsBusiness Operations and Strategy
Benchmark Holdings Announces Strategic Shift Post-Genetics Business Sale
Neutral
May 23, 2025

Benchmark Holdings PLC has announced a series of proposals following the disposal of its Genetics Business, including the return of capital to shareholders and the cancellation of its shares from trading on AIM and Euronext Growth Oslo. The company plans to re-register as a private limited company and offer a tender for shareholders to realize their investments, with a special dividend planned post-tender. These moves aim to streamline operations and focus on future growth, with implications for shareholder structure and market presence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2025